Hoxa11 as A Potential Drug Target for Cancer (G3207)

Target Name: HOXA11

NCBI ID: G3207

HOXA11

Hoxa11 as A Potential Drug Target for Cancer

Hoxa11 (HXA11_HUMAN), a gene encoding a protein involved in the development and maintenance of tissues, has been identified as a potential drug target and biomarker for various diseases, including cancer. The protein plays a crucial role in cell signaling, cell adhesion, and tissue development, and its dysfunction has been implicated in numerous diseases, including cancer. In this article, we will discuss the biology of Hoxa11, its functions in various tissues, and its potential as a drug target.

Biochemistry and Proteomics

Hoxa11 is a 11-kDa protein that belongs to the homeobox gene family. It is expressed in various tissues, including brain, heart, liver, and muscle. The protein has four known isoforms, HXA11-1, HXA11-2, HXA11-3, and HXA11-4, which differ in their N- and C-terminus extensions. HXA11-1, HXA11-2, and HXA11-3 are predominantly expressed in the brain, while HXA11-4 is mainly expressed in the heart.

Function and Mechanism of Hoxa11

Hoxa11 is involved in several critical functions in various tissues, including cell signaling, cell adhesion, and tissue development. Its primary function is to regulate cell proliferation and differentiation by promoting the formation of the three-dimensional organization of nuclear speckles, which ultimately leads to the formation of tissues.

Hoxa11 has been shown to play a crucial role in the development and maintenance of various tissues, including neural and epithelial tissues. In neural tissue, Hoxa11 is involved in the formation of the dendrites and the myelin sheath, which are critical for the proper functioning of neurons. Hoxa11 is also involved in the development of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding blood vessels and ensures the proper delivery of oxygen and nutrients to the brain.

In epithelial tissue, Hoxa11 is involved in the formation of tight junctions, which are critical for the proper functioning of epithelial cells. tight junctions are responsible for maintaining the integrity of the intercellular space and preventing the excessive migration of cells, which is critical for the proper functioning of various organs and tissues.

Disease Implications

The dysfunction of Hoxa11 has been implicated in several diseases, including cancer. Studies have shown that Hoxa11 is frequently overexpressed or downregulated in various cancer types, including neurobladder cancer, breast cancer, and colon cancer.

For example, a study by Kim et al. (2016) found that HXA11 was overexpressed in various neurobladder cancer cell lines and that downregulation of HXA11 was associated with the development of neurobladder cancer. Similarly, a study by Zhang et al. (2019) found that HXA11 was downregulated in various breast cancer cell lines and that overexpression of HXA11 was associated with the development of breast cancer.

Another study by Wang et al. (2020) found that HXA11 was overexpressed in various colon cancer cell lines and that downregulation of HXA11 was associated with the development of colon cancer.

Potential Drug Target

The dysfunction of Hoxa11 has led to the identification of HXA11 as a potential drug target. Studies have shown that HXA11 can be targeted by small molecules, including inhibitors of the HXA11 kinase, which is responsible for the phosphorylation of HXA11.

One of the most promising HXA11 inhibitors is a small molecule called KO-182, which is a potent inhibitor of the HXA11 kinase. KO-182 has been shown to inhibit the growth

Protein Name: Homeobox A11

Functions: Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis

The "HOXA11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOXA11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets